Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hjelm

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
International Journal of Cancer|March 12, 1993
Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be inducedP Ragnhammar, J Fagerberg, J E Frödin, et al.
British Journal of Cancer|June 27, 2002
Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgeryJ Tennvall, G Lundell, P Wahlberg, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1991
Chemotherapy and immunotherapy of colorectal cancerG Masucci, P Ragnhammar, J E Frödin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2A L Hjelm Skog, M Wadhwa, M Hassan, et al.
Annals of the New York Academy of Sciences|July 27, 2000
Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinomaH Mellstedt, J Fagerberg, J E Frödin, et al.
Lakartidningen|September 23, 1981
[Reference values of lead in blood and urine in adults]K Anderson, K Andersson, M Botvalde, et al.
Seminars in Oncology|October 1, 1991
The therapeutic use of monoclonal antibodies in colorectal carcinomaH Mellstedt, J E Frödin, G Masucci, et al.
Cancer Biotherapy|January 1, 1995
Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II studyA L Hjelm, P Ragnhammar, J Fagerberg, et al.
Current Opinion in Hematology|May 5, 1999
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factorsH Mellstedt, J Fagerberg, J E Frödin, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1991
Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF)H Mellstedt, J E Frödin, P Ragnhammar, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Cancer|March 12, 1993
Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be inducedP Ragnhammar, J Fagerberg, J E Frödin, et al.
British Journal of Cancer|June 27, 2002
Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgeryJ Tennvall, G Lundell, P Wahlberg, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1991
Chemotherapy and immunotherapy of colorectal cancerG Masucci, P Ragnhammar, J E Frödin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2A L Hjelm Skog, M Wadhwa, M Hassan, et al.
Annals of the New York Academy of Sciences|July 27, 2000
Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinomaH Mellstedt, J Fagerberg, J E Frödin, et al.
Lakartidningen|September 23, 1981
[Reference values of lead in blood and urine in adults]K Anderson, K Andersson, M Botvalde, et al.
Seminars in Oncology|October 1, 1991
The therapeutic use of monoclonal antibodies in colorectal carcinomaH Mellstedt, J E Frödin, G Masucci, et al.
Cancer Biotherapy|January 1, 1995
Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II studyA L Hjelm, P Ragnhammar, J Fagerberg, et al.
Current Opinion in Hematology|May 5, 1999
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factorsH Mellstedt, J Fagerberg, J E Frödin, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1991
Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF)H Mellstedt, J E Frödin, P Ragnhammar, et al.
Pageof 3